nejm tirzepatide SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants 🔴Tirzepatide as Compared with Semaglutide

The NHS recommends drinking 6-8 glasses of fluid daily, though patients with heart failure, kidney disease or other conditions requiring fluid restriction should follow their clinician's specific advice

Do not combine with semaglutide or tirzepatide

Provincial pharmacy regulators and Health Canada have strictly prohibited the mass-production of compounded semaglutide copies because safe, approved brand-name versions are already commercially available

This loss accelerates during perimenopause and menopause due to declining estrogen levels

This condition is remarkably common, affecting more than half of adults over age 60 in the United States

The GLP-1RAs have also been associated with minimal or no proteinuria reduction in small studies including kidney transplant recipients